Interim Supply of Finnish and Norwegian Stock to Mitigate Supply Disruption

To ensure continuity in supply, Janssen-Cilag Ltd (a Johnson & Johnson Company) has obtained approval from the MHRA to supply Finnish product – Concerta 27 mg and Norwegian product Concerta 27 mg, which were expected to be on the UK market from 15th December 2024 to 15th March 2025.

Based on the MHRA approval (March 2025) these products are expected to be available on the market until 30th April 2025 without need to update DHPC letter.